卵巢刺激方案不影响非整倍体率或囊胚率
这项回顾性、观察性、多中心队列研究纳入8466例接受自体卵母细胞IVF及胚胎植入前非整倍体遗传学检测的患者,按促性腺激素总剂量(<3000 IU或≥3000 IU)分组并按母亲年龄分层。结果显示两组非整倍体率、妊娠结局及累积活产率相似,囊胚率无统计学差异;促性腺激素用量较高组中年轻女性非整倍体率较低(P<0.001),但高龄女性无统计学差异。
要点
- 促性腺激素总剂量<3000 IU或≥3000 IU两组的非整倍体率、妊娠结局及累积活产率相似。
- 促性腺激素用量较高组中年轻女性非整倍体率较低(P<0.001),高龄女性无统计学差异。
- 作者认为HMG的使用应根据个体特征和不孕类型逐例评估。
核心结论
- 高剂量促性腺激素与非整倍体率无关,但年轻女性中HMG比例增加与非整倍体率降低相关。
- 促性腺激素总剂量不影响非整倍体率、生殖结局或累积活产率,HMG的使用应根据个体特征和不孕类型逐例评估。
研究设计与样本
- 回顾性、观察性、多中心队列研究,共纳入8466例接受自体卵母细胞IVF及胚胎植入前非整倍体遗传学检测的患者。
- 按促性腺激素总剂量(<3000 IU或≥3000 IU)分组,并按母亲年龄分层。
主要发现
- 促性腺激素总剂量<3000 IU或≥3000 IU两组的非整倍体率、妊娠结局及累积活产率相似,囊胚率无统计学差异。
- 卵巢刺激期间接受较高HMG用量的女性非整倍体率较低(P=0.02)。
- 按年龄分层后,年轻女性中较高HMG用量者非整倍体率较低(P<0.001),高龄女性中较高或较低HMG用量者无统计学差异。
- IVF结局或累积活产率无显著差异。
临床怎么用
- 作者认为HMG的使用应根据个体特征和不孕类型逐例评估。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Could the total dose (<3000 IU or ≥3000 IU) and type of exogenous gonadotrophin (i.e. recombinant FSH and/or human menopausal gonadotrophin [HMG]) influence aneuploidy and blastulation rates and produce different reproductive outcomes? DESIGN: This retrospective, observational, multicentre cohort study included a total of 8466 patients undergoing IVF using autologous oocytes and preimplantation genetic testing for aneuploidies. Participants were divided according to the dosage of total gonadotrophins and stratified by maternal age. RESULTS: The aneuploidy rates, pregnancy outcomes and cumulative live birth rates (CLBR) were similar among women who received total gonadotrophin dosages of <3000 or ≥3000 IU. No statistical differences were reported in the blastulation rate with lower or higher gonadotrophin dosages. Women receiving a higher amount of HMG during ovarian stimulation had a lower aneuploidy rate (P = 0.02); when stratified according to age, younger women with a higher HMG dosage had lower aneuploidy rates (P< 0.001), while no statistical differences were observed in older women with higher or lower HMG dosages. No significant differences were observed in IVF outcomes or CLBR. CONCLUSIONS: High doses of gonadotrophins were not associated with rate of aneuploidy. However, an increased fraction of HMG in younger women was associated with a lower aneuploidy rate. The study demonstrated that the total gonadotrophin dosage did not influence aneuploidy, reproductive outcomes or CLBR. The increased gonadotrophin and HMG dosages used for ovarian stimulation did not precede aneuploidy, and the use of HMG should be evaluated on a case-by-case basis, according to the individual's characteristics and infertility type.
引用
- Cozzolino M, Mossetti L, Mariani G, et al. The ovarian stimulation regimen does not affect aneuploidy or blastocyst rate. Reprod Biomed Online. 2024. PMID: 38838468. doi:10.1016/j.rbmo.2024.103851
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。